A Covelli
Overview
Explore the profile of A Covelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
166
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Apte S, Majumdar S, Agborsangaya C, Rueda-Clausen C, Klarenbach S, Sharma A, et al.
Can J Surg
. 2025 Jan;
57(4suppl1):S85-S139.
PMID: 39818541
No abstract available.
2.
Genta S, Araujo D, Hueniken K, Pipinikas C, Ventura R, Rojas P, et al.
ESMO Open
. 2024 Nov;
9(11):103978.
PMID: 39549683
Background: Locally advanced melanoma has a variable prognosis. Currently, there are no reliable criteria to stratify the risk of disease relapse and identify those patients who will benefit the most...
3.
Bodie G, Hagen J, Almamar A, Majumdar S, Wang X, Tuepah R, et al.
Can J Surg
. 2022 Apr;
55(4 Suppl 1):S63-S135.
PMID: 35488395
No abstract available.
4.
Hoffmann V, Baccarani M, Hasford J, Lindoerfer D, Burgstaller S, Sertic D, et al.
Leukemia
. 2015 Mar;
29(6):1336-43.
PMID: 25783795
This population-based registry was designed to provide robust and updated information on the characteristics and the epidemiology of chronic myeloid leukemia (CML). All cases of newly diagnosed Philadelphia positive, BCR-ABL1+...
5.
Visani G, Milligan D, Leoni F, Chang J, Kelsey S, Marcus R, et al.
Leukemia
. 2001 May;
15(5):764-71.
PMID: 11368437
PSC 833 (Valspodar) can reverse multidrug resistance (MDR) in patients with hematologic malignancies, but alters the pharmacokinetics of concomitant anticancer agents. A phase I, dose-finding study was initiated to define...
6.
Tidefelt U, Liliemark J, Gruber A, Liliemark E, Sundman-Engberg B, Juliusson G, et al.
J Clin Oncol
. 2000 Apr;
18(9):1837-44.
PMID: 10784624
Purpose: The aim of the present study was to evaluate the effect of the cyclosporine derivative valspodar (PSC 833; Amdray, Novartis Pharma, Basel, Switzerland) on the concentration of daunorubicin (dnr)...
7.
Covelli A
Ann Oncol
. 2000 Feb;
10 Suppl 6:53-9.
PMID: 10676553
The term multidrug resistance (MDR) describes the observation that tumour cell lines can become cross-resistant to several structurally unrelated chemotherapeutic agents after exposure to a single cytotoxic drug. In hematological...
8.
Gemperli B, Covelli A, Burke G
Ann Oncol
. 2000 Feb;
10 Suppl 6:15-7.
PMID: 10676548
Major opportunities exist for patients, investigators and the pharmaceutical industry in oncology drug development in Central and Eastern Europe. Novel therapeutics may be offered for investigational use in selected centres...
9.
Advani R, Visani G, Milligan D, Saba H, Tallman M, Rowe J, et al.
Adv Exp Med Biol
. 1999 Sep;
457:47-56.
PMID: 10500779
The failure of convenional chemotherapy in relapsed or refractory and other poor risk AML patients has been linked to expression of the multidrug resistance gene (mdr 1) product P-glycoprotein (P-gp)....
10.
Covelli A
Tumori
. 1998 Jan;
83(5 Suppl):S21-4.
PMID: 9446255
SDZ PSC 833 is a novel compound able to reverse the resistance to chemotherapy of cancer cells with the multidrug resistance (MDR) phenotype by inhibiting the 170 kd P-glyco-protein (P-gp)....